Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Gain Therapeutics, with a price target of $5.00.

Thomas Shrader has given his Buy rating due to a combination of factors that, in his view, de-risk Gain Therapeutics’ lead program and validate its platform. He highlights that recent clinical data for GT-02287 show consistent reductions in CSF glucosylsphingosine among Parkinson’s patients who started with elevated levels, which he interprets as clear evidence that the drug is enhancing GCase activity in the brain. Because this biomarker is widely regarded as a robust indicator of GCase function, Shrader sees the results as strong proof-of-mechanism for GT-02287 and an important confirmation that Gain’s allosteric modulation strategy is working as intended.

At the same time, Shrader emphasizes that the new findings build on extensive preclinical work showing GT-02287 can improve GCase function in both lysosomes and mitochondria, reduce mitochondrial stress, and enhance neuronal survival in multiple disease models. He notes that these data, together with prior evidence of improved GCase trafficking, suggest the compound may address both wild-type and mutant enzyme dysfunction, which broadens its potential utility in Parkinson’s disease. Shrader also points to the possibility of future partnerships leveraging the same allosteric “molecular staple” approach in other enzyme-deficiency disorders, which he believes could create additional value beyond the lead asset. In his valuation framework, these scientific and clinical derisking steps, combined with the upside from upcoming data and partnering opportunities, support maintaining a Buy recommendation on GANX.

According to TipRanks, Shrader is a 4-star analyst with an average return of 4.1% and a 38.11% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Gain Therapeutics, Aldeyra Therapeutics, and Harrow Health.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.